Hengeler Mueller advises Paragon Partners on voluntary public purchase offer for APONTIS PHARMA

APONTIS PHARMA and Zentiva Group have signed an investor agreement on the basis of which Zentiva Group will launch a voluntary public purchase offer for the shares of APONTIS PHARMA. In this context, funds advised by Paragon Partners have entered into a purchase agreement for the sale of an approx. 37.5% stake in APONTIS PHARMA to Zentiva Group.

Hengeler Mueller is advising Paragon Partners on the transaction.

Hengeler Mueller team for Paragon

M&A/Corporate: Martin Ulbrich, Oda Christiane Goetzke (both lead, partner, Düsseldorf), Jasmin Atta-Schumacher, Tim Jaeger (both associates, both Düsseldorf),

Regulatory: Jan Schülting (senior associate, Düsseldorf),

Antitrust:  Philipp Otto Neideck (partner, Düsseldorf).